[1] |
GENG Hongjiao, WANG Lianxin, XIE Yanming.
Pharmacovigilance of Chinese Medicine in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 552-555.
|
[2] |
SA Rina, ZHANG Bing, LIN Zhijian, WANG Xiaofang, ZHANG Xiaomeng.
Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 422-426.
|
[3] |
SHEN Mengqiu, LI Ming, WANG Jiayu, GAN Ge, LIU Pengcheng, SUN Jun.
Sampling Investigation of Current Situalion of Pharmacovigilance in Pharmaceutical Manufacturers in Jiangsu Province
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 133-137.
|
[4] |
FENG Yanan, LIU Xinxin, LI Yonghui, WANG Fang, GUO Ruifeng.
Challenges to Pharmacovigilance by Medical Institutions under the New Drug Administration Law
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 572-573.
|
[5] |
HUANG Yuan, WANG Chenggang, WU Shifu, WANG Ling, TIAN Yuejie, WU Chen, WANG Xiaojun.
Drug Abuse Monitoring Models in Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 607-612.
|
[6] |
HOU Yongfang, TIAN Chunhua, LIU Hongliang, LIU Cuili, LI Ming, WANG Xinmin.
Study on Applicability of ICH Guideline M1 Mapping Practice of National Adverse Drug Reaction Terminology
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 333-337.
|
[7] |
MA Danhua, LIU Hongliang, WANG Dan, LI Ming, TIAN Chunhua.
Study on Applicability of ICH Guideline M1 Mapping Feasibility of National Adverse Drug Reaction Terminology
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 329-332.
|
[8] |
WANG Dan, LI Xinling, DONG Duo, XIONG Weiyi, LIU Cuili, ZHU Lan, GENG Fengying, LIAO Jianbo, YANG Yueming, LAN Shan, LV Xiaoqin, WANG Tongchun, ZHAO Xia, WANG Wen.
Investigation of Pharmaceutical Manufacturers’ Ability of Direct Reporting of Drug Adverse Reactions
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 654-661.
|
[9] |
SHI Bing-juan.
Thinking on Improving and Guaranteeing the Quality of Traditional Chinese Medicine Preparations in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 276-279.
|
[10] |
WANG Dan.DONG Duo.
Exploration on Direct Reporting System of Adverse Drug Reactions by Marketing Authorization Holders
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 648-651.
|
[11] |
LI Ang, ZHANG Bing, ZHANG Xiao-meng, SUN Xiao-xia, YANG Xue, LI Fan.
Investigation on the Situation of Cognition and Reporting of Adverse Drug Reactions in 1 109 Basic Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 289-294.
|
[12] |
SUN Jun, HUANG Qian-qian, GAN Ge, WANG Jia-yu.
Discussion on the Strategy of Drug Manufacturers to Deal with the Adverse Drug Event Clustering Signal
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(11): 671-674.
|
[13] |
TIAN Chun-hua .
Thinking to Promote Adverse Drug Reaction Monitoring Work of Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 272-274.
|
[14] |
.
TIAN Ke-ren1 GAO Jing2 MIU Jian3 WAN Kai-hua2 YU Chao2 ZHOU Juan2 XU Jin2 LI Sui2
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(5): 285-287.
|
[15] |
REN Jing-tian, ZHENG Wen-ke, ZHANG Jun-hua, LEI Xiang, YANG Le, GUO Xiao-xin, SHANG Hong-cai, DU Xiao-xi.
Role of Drug Manufacturers in Post-marketed Drug Risk Management
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(2): 88-93.
|